For All The Latest Medical News, Health News, Research News, COVID-19 News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Cardiology News, Epigenetic News, Cancer News, Doctor News, Hospital News
Vaccine iNews is a new segment dedicated to progress about about COVID-19 vaccines. and other vaccines. Currently there is a lot of controversy and issues surrounding COVID-19 vaccines and this new segment will not only address these but also provides updates about COVID-19 vaccines developments and progress. There are almost close to 168 COVID Vaccines being developed but 3 of the main covid-19 ...
Vaccine News: Pharmaceutical giant Johnson & Johnson announced on late Monday that it had temporarily halted its COVID-19 vaccine trial because one of its participants had become seriously sick.
A spokesman for Johnson and Johnson told Thailand Medical News, "We have halted further dosing in all our COVID-19 vaccine candidate clinical trials globally due to a particpant...
COVID-19 Help: While tens of thousands are getting infected daily and thousands are dying each day, millions elsewhere are worried and are trying to find ways to help themselves and their loved ones and the only thing that stupid health authorities and incompetent corrupted governments around the world are doing are giving false hopes by an anticipated COVID-19 vaccine that many think will solve t...
Source: COVID-19 Vaccines Oct 08, 2020 4 years ago
COVID-19 Vaccines: A group of American researchers from the Swedish Medical Center-Seattle, University of Washington-Seattle, Stanford University-California, LabCorp-Seattle and the Vaccine and Infectious Disease Division, Fred Hutch-Seattle after reviewing a case of a patient who got re-infected with a different strain of the SARS-CoV-2 coronavirus ie the more potent and infectious D614G mu...
Vaccine News: Researchers from Harvard’s Wyss Institute for Biologically Inspired Engineering and John A. Paulson School of Engineering and Applied Sciences (SEAS) along with support from Perelman School of Medicine, University of Pennsylvania, have developed a platform technology that uses red blood cells to deliver antigens to antigen-presenting cells (APCs) in the spleen, generating ...
Medical Law: According to a new research paper in the journal Science co-written by a University of Illinois, Urbana-Champaign legal expert who studies the policy implications of advanced biotechnologies. well-intentioned “citizen scientists” developing homemade COVID-19 vaccines may believe they are inoculating themselves against the ongoing pandemic, but the pract...
Source: Vaccines-COVID-19 Oct 01, 2020 4 years ago
Vaccines-COVID-19: The NIAID And Moderna Inc Phase 1 clinical trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults.
The trial results were published in the New England Journal of Medicine. https://www.nejm.org/doi/10.1056/NEJMoa2028436
The new experimental v...
Source: COVID-19 Vaccine Exclusive Sep 29, 2020 4 years ago
COVID-19 Vaccine Exclusive: Adeno-associated viral vectors to deliver gene therapies and vaccines are a growing platform that is being used by more and more pharmaceutical companies in drug and vaccine development. But unknown to many there are possible repercussions taking such AAV vectors based meds or vaccines.
Two gene therapies using adeno-associated virus (AAV) vectors to deliver ge...
COVID-19 Vaccine : The AIDS Healthcare Foundation (AHF), the largest global AIDS organization, today (Monday,14th September) sharply criticized pharmaceutical and biotech companies working on COVID-19 vaccines over a near total lack of transparency on the companies’ respective trials, including setbacks with AstraZeneca’s vaccine trial that briefly forced its suspensio...
Source: Vaccines-COVID-19 Sep 14, 2020 4 years ago
Vaccines-COVID-19: Indian researchers from vaccine developer Bharat Biotech International Ltd in collaboration with researchers National Institute of Virology-Indian Council of Medical Research have conducted a preclinical study demonstrating the safety and efficacy of a new candidate vaccine against the SARS-CoV-2 coronavirus, the pathogen that causes the COVID-19 disease.
The ...
Source: Vaccines-COVID-19 Sep 13, 2020 4 years ago
Vaccines-COVID-19: The world’s oral recombinant adenoviral mucosal COVID-19 vaccine by Vaxart, Inc, a California based biotechnology company that is administered by tablet rather than by injection, has demonstrated positive results in a inducing potent systemic and mucosal immune responses in preclinical studies.
The study findings were published on a preprint server and are current...
Source: COVID-19 Immunity Sep 09, 2020 4 years ago
COVID-19 Immunity is short-lived for those who had mild symptoms when they were first infected with the SARS-CoV-2 coronavirus or were asymptomatic according to a new study by Chinese researchers from the Army Medical University in Chongqing led by Dr Ye Lilin, a leading Immunologist from the University’s Institute of Immunology.
The study also indicates that the absence of the key ...
Vaccine-COVID-19: It was announced the last few hours that the large phase 3 clinical trial of the COVID-19 vaccine AZD1222 developed by the University of Oxford and Astrazenaca was stopped in the last 24 hours and put on hold as a result of reported serious adverse reactions.
The sudden stoppage affected numerous testing sites globally especially in the United States and United Kingdom a...
Source: COVID-19 Next Generation Vaccines Sep 07, 2020 4 years ago
COVID-19 Next Generation Vaccines: Cambridge based Elicio Therapeutics has developed a next generation COVID-19 vaccine ELI-005 that is expected to start initial clinical trials soon. Unlike most of the current genetic based vaccines under development or in phase 3 trials, this lymph node-targeting vaccine is composed of an adjuvant developed using the company’s Amphiphile technology and the...
COVID-19 Vaccine researchers from UK and Taiwan have demonstrated the potential of a new candidate vaccine called RBD-SpyVLP against the SARS-CoV-2 coronavirus in animal models.
In vivo trials involving animal models such as mice and pigs, low doses of the vaccine triggered a potent neutralizing antibody response that was stronger than the response induced by serum taken from patients who...
COVID-19 Vaccine: New studies are showing that T cell immunity is necessary to provide robust and durable protection against reinfection with the SARS-CoV-2 coronavirus. This implies that the epitopes specific to the SARS-CoV-2 coronavirus which are capable of eliciting this type of response across a huge number of individuals need to be identified.
An epitope, also known as ant...
COVID-19 Vaccine: The chief of the US Food and Drug Administration, Dr Stephen Hahn raised the possibility that a vaccine against the SARS-CoV-2 coronavirus might be given emergency approval even before the end of trials designed to ensure its safety and effectiveness.
However such a request for extraordinary approval would have to come from the vaccine developer, Dr Stephen Hah...
COVID-19 Vaccine: A media release by Agence France-Presse(AFP) reports that a senior Catholic archbishop has warned he is "deeply troubled" by Australia's vaccine deal with AstraZeneca, saying the potential vaccine uses a fetal cell line that creates an "ethical quandary" for Christians.
This is the first time that Thailand Medical News is aware that fetal cell lin...
COVID-19 Vaccine: Researchers from Washington University School of Medicine-St. Louis have developed a vaccine that targets the SARS-CoV-2 coronavirus and can be administered through the nose in one dose.
Studies in mice models susceptible to the SARS-CoV-2 coronavirus have proven to be effective in preventing infection.
The study team next plans to test the vaccine in nonhuman pri...
Source: COVID-19 Vaccines Aug 21, 2020 4 years ago
COVID-19 Vaccines: Pfizer Inc. and BioNTech has released additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against SARS-CoV-2, which has advanced into Phase 2/3 evaluation.
The clinical data is published on a preprint server and is pending peer-review. https://www.medrxiv.org/content/10.1101/2020.08...
COVID-19 Vaccine: A new vaccine made from a mild virus genetically modified to carry a key gene from the SARS-CoV-2 coronavirus is effective at preventing pneumonia in mice infected with the COVID-19 virus, according to research findings from Washington University School of Medicine in St. Louis.
Co-senior author Dr Michael S. Diamond, MD, PhD, the Herbert S. Gasser Profess...
COVID-19 Vaccine: Results of the phase one trial of NovaVAx’s NVX-CoV2373 recombinant nanoparticle vaccine that is manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic including inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized COVID-19 patients.
Though several promising candidates are already on...
COVID-19 Vaccine: Biotech and medical researchers from the University of Chicago and Duke University have created a new vaccine technology platform that allows the generation of the more effective vaccines with the fewest side effects using self-assembling peptide nanofibers tagged with antigens to prime the immune system against a potential invasion.
The research findings were published ...
Source: COVID-19 Vaccines Aug 07, 2020 4 years ago
COVID-19 Vaccines: As the world eagerly anticipates the arrival of a truly effective COVID-19 vaccine, it is emerging that one country is most likely to least benefit from it despite spending the most money compared to any other country in the world to secure a sufficient supply of the vaccine for its population.
In the United States where more than 42 percent of its population is obese, ...
COVID-19 Vaccine: Maryland-based Novavax is yet another biopharma company reporting promising early-stage data for a potential COVID-19 vaccine.
The biopharma company announced data from Phase I of its Phase I/II placebo-controlled trial of its vaccine with and without Matrix-M adjuvant. The trial was conducted in healthy adults 18 to 59 years of age.
The vaccin...
COVID-19 Vaccine: Russia’s Minister for Health Mikhail Murashko announced that Russia is planning a nationwide program to vaccinate its population against COVID-19 starting in October. The vaccine has not yet completed clinical trials. Murashko indicated they would begin by vaccinating teachers and health care workers.
He also told the RIA state news agency that while in t...
Source: COVID-19 Vaccines Aug 03, 2020 4 years ago
COVID-19 Vaccines: American researchers from ImmunityBio Inc. and Icahn School of Medicine at Mount Sinai in New York have developed a next generation COVID-19 vaccine: the bivalent human adenovirus serotype 5 (hAd5) vaccine for inducing both cellular and humoral immunity against the SARS-CoV-2 coronavirus, using both an S protein sequence optimized for cell surface expression...
Source: COVID-19 Vaccines Jul 29, 2020 4 years ago
COVID-19 Vaccines: Research scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health report that two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2.
 ...
Source: COVID-19 Vaccine News Jul 26, 2020 4 years ago
COVID-19 Vaccine News: Dynavax Technologies, a fully-integrated biopharmaceutical based in California has partnered with Taiwan-based Medigen Vaccine Biologics to develop a new adjuvanted Covid-19 vaccine candidate.
The new collaborative vaccine development will leverage on Medigen’s stable prefusion form of the SARS-CoV2 recombinant spike protein in combination with Dynavax&rs...
COVID-19 Vaccine: California based Arcturus Therapeutics Holdings Inc., a clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, and Duke-NUS Medical School, Singapore's flagship research-intensive graduate entry medical school, announced that the Clinical Trial Application for COVID-19 vaccine ...
Source: COVID-19 Vaccine Progress Jul 22, 2020 4 years ago
COVID-19 Vaccine Progress: The Phase ½ clinical trial of BioNTech And Pfizer’s BNT162b1 RNA-Based Vaccine has demonstrated that the vaccine is able to elicit both T Cell And Neutralizing Antibodies Response.
The trial results were published by researchers from Germany and the United States on a preprint server and are yet to have been peer-reviewed. https://www.medrxiv.org/co...
Source: COVID-19 Vaccine Updates Jul 21, 2020 4 years ago
COVID-19 Vaccine Updates: The clinical trial results of the Phase I/II trial of Oxford University and AstraZenaca’s ChAdOx1 nCoV-19 vaccine published in the scientific journal, The Lancet, indicate no early safety concerns and induces strong immune responses in both parts of the immune system. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext
The ChA...
COVID-19 Vaccine: The phase 2 trial of China’s Ad5 vectored COVID-19 vaccine candidate that was conducted in Wuhan has found that the vaccine is safe and induces an immune response, according to trial findings published in The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext#%20
The phase 2 randomized trial sought to evaluate the ...
COVID-19 Vaccine: It was announced that the First Phase-III clinical trial of Chinese state-owned pharmaceutical company Sinopharm's inactivated Covid-19 vaccine has started in Abu Dhabi.
Head of Abu Dhabi’s health department becomes first volunteer for
Covid-19 Phase III Chinese vaccine trials
Interestingly the UAE health authorities recently issued a permit for up to 15,000 vo...
COVID-19 Vaccine: Moderna has announced that said its COVID-19 vaccine candidate mRNA-1273 will advance to a 30,000-participant Phase III trial later this month, following publication of additional positive Phase I data from a study led by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
The “COVE” Phase III study (NCT04470427) is expected to begin regis...
COVID-19 Vaccine Updates: Data from the Phase 1 trial of COVID-19 vaccine by AstraZeneca and Oxford University’s Jenner Institute is showing a robust defense against the novel coronavirus that has infected more than 13.6 million individuals across the globe
U.K. media yesterday began to report hints of data from the early-stage study of the vaccine candidate...
COVID-19 Vaccine: The Phase 1 trial of an investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes COVID-19 disease, was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to US NIH authorities.
The interim results of the trial were published yesterday in The New England Journal of Medicine....
COVID- 19 Vaccine: Canadian biophamaceutical company Medicago that is based in Quebec with branches in the U.S. announced that it has begun Phase I clinical trial for its plant-derived COVID-19 vaccine candidate. It has already administered the first doses of the candidate in healthy human subjects, and the company intends to initiate a Phase II/III trial this coming October.
Dr Nath...
COVID-19 Vaccine: American researchers from Duke University-Durham have made an important discovery about the spike protein SARS-CoV-2 that could have a broad impact on vaccine studies.
The S or spike protein is the structure that binds to host cell angiotensin-converting enzyme 2 (ACE2) to enable viral attachment and entry during the infection process. The spike protein is also...
COVID-19 Vaccine: There are more than 140 SARS-CoV-2 vaccines in development and the race for a successful candidate to help prevent COVID-19 is making many researchers jumpstart processes and in some cases even by pass safety protocols.
Although an effective and safe vaccine would be a major advance in the fight against COVID-19, there are challenges in evaluating the efficacy of&nb...
COVID-19 Vaccine: Maryland based Altimmune, Inc., a clinical-stage biopharmaceutical company, has reported positive results from the preclinical studies conducted in mice at the University of Alabama at Birmingham of its intranasal COVID-19 vaccine candidate, AdCOVID.
The research studies; a collaboration between the University of Alabama-Birmingham and Altimmune showed strong serum neutr...
Source: COVID-19 Vaccines Jul 10, 2020 4 years ago
COVID-19 Vaccines: The U.S.National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.
Various media have recently reported that sponsor companies are struggling to enroll patients in clinical trials for COVID-19 va...
Source: COVID-19 Vaccine Updates Jul 08, 2020 4 years ago
COVID-19 Vaccine Updates: Maryland based Biotech company Novavax announced that it has been awarded US$1.6 billion toward late-stage clinical trials and large-scale manufacturing to produce 100 million doses of its COVID-19 vaccine starting this year through the Trump’s administration “Operation Warp Speed” program.
The new funding will enable Novavax to complete la...
Source: COVID-19 Vaccine News Jul 07, 2020 4 years ago
COVID-19 Vaccine News: Biotech manufacturing company-Emergent BioSolutions, based in Maryland, entered a five-year manufacturing services deal with Janssen Pharmaceutical, a Johnson & Johnson company, to manufacture J&J’s Ad26.COV2-S COVID-19 vaccine. Emergent will handle contract development and manufacturing (CDMO) services in a deal that is valued at ...
Source: COVID-19 Vaccine Updates Jul 07, 2020 4 years ago
COVID-19 Vaccine Updates: It was announced that vaccine candidate COVAX-19 developed by Vaxine Pty Ltd and Flinders University will commence Phase 1 trials at the Royal Adelaide Hospital (RAH) to test its efficacy.
The phase I trial will provide initial safety and immune response data on 40 healthy participants aged between 18 and 65 years who have already been pre-screened.
Resear...
COVID-19 Vaccine: Professor of vaccinology at the University of Oxford, and one of the scientists leading the vaccine initiative, Dr Sarah Gilbert, told the U.K.'s Science and Technology Committee last week that their candidate vaccine has progressed to the phase III trial in the United Kingdom.
Phase III trials typically involves tens of thousands of research participants acros...
COVID-19 Vaccine: Researchers from China have created an artificial protein that they say could be the basis of a vaccine to help ward off various deadly coronaviruses, including the pathogen that causes Covid-19
Copyright: Credit: Xinhua
The researchers from the Chinese CDC said the approach triggered a strong antibody response in mice and monkey trials to Middle Eas...
COVID-19 Vaccine: Indian pharmaceutical company, Zydus Cadila received the green signal from the Drug Controller General of India (DGCI) to start phase I and II of their clinical trials on human participants.
Over 120 independent scientific bodies are in contention to find a potential COVID-19 vaccine. Over 7 vaccines are being researched in India and just this week, two candidate groups ...
Source: COVID-19 Vaccine Updates Jul 04, 2020 4 years ago
COVID-19 Vaccine Updates: Pharmaceutical and Biotech giants, Pfizer and BioNTech reported that the most advanced of four constructs of their messenger RNA (mRNA) vaccine candidate for COVID-19 showed encouraging immunogenicity and a favorable safety profile in preliminary Phase I/II data published in a preprint study. https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1
Bot...
COVID-19 Vaccine: Members of the National Institutes of Health's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Vaccines Working Group assess practical considerations and prerequisites for using controlled human infection models (CHIMs), which can be used for human challenge studies, to support SARS-CoV-2 vaccine development.
In a new report published in th...